CR10161A - IMMUNOGLOBULINS - Google Patents

IMMUNOGLOBULINS

Info

Publication number
CR10161A
CR10161A CR10161A CR10161A CR10161A CR 10161 A CR10161 A CR 10161A CR 10161 A CR10161 A CR 10161A CR 10161 A CR10161 A CR 10161A CR 10161 A CR10161 A CR 10161A
Authority
CR
Costa Rica
Prior art keywords
immunoglobulins
Prior art date
Application number
CR10161A
Other languages
Spanish (es)
Inventor
Claire Ashman
Martin John Cassidy
Jane Elizabeth Clarkson
Jonathan Henry Ellis
Trevor Anthony Kenneth Wattam
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35997844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10161(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR10161A publication Critical patent/CR10161A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • A61P33/12Schistosomicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CR10161A 2006-01-11 2008-07-17 IMMUNOGLOBULINS CR10161A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0600488.1A GB0600488D0 (en) 2006-01-11 2006-01-11 Immunoglobulins

Publications (1)

Publication Number Publication Date
CR10161A true CR10161A (en) 2008-11-26

Family

ID=35997844

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10161A CR10161A (en) 2006-01-11 2008-07-17 IMMUNOGLOBULINS

Country Status (18)

Country Link
EP (1) EP1976881A2 (en)
JP (1) JP2009523154A (en)
KR (1) KR20080113201A (en)
CN (1) CN101370829A (en)
AR (1) AR058955A1 (en)
AU (1) AU2007204372A1 (en)
BR (1) BRPI0706481A2 (en)
CA (1) CA2635972A1 (en)
CR (1) CR10161A (en)
EA (1) EA200801520A1 (en)
GB (1) GB0600488D0 (en)
IL (1) IL192207A0 (en)
MA (1) MA30156B1 (en)
NO (1) NO20082767L (en)
PE (1) PE20081185A1 (en)
TW (1) TW200736274A (en)
WO (1) WO2007080174A2 (en)
ZA (1) ZA200805526B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
EP2027157B1 (en) 2006-05-25 2014-08-06 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EA201100653A1 (en) * 2008-11-26 2011-12-30 Глаксо Груп Лимитед LIGANDS CONNECTING INTERLAYKIN-13 (IL-13)
SG173705A1 (en) 2009-03-05 2011-09-29 Abbott Lab Il-17 binding proteins
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
WO2010136481A1 (en) 2009-05-28 2010-12-02 Glaxo Group Limited Il-13 binding protein
EP3037104B1 (en) * 2009-10-20 2020-05-27 AbbVie Inc. Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
CA2814431A1 (en) * 2010-10-15 2012-04-19 Medimmune Limited Therapies for improving pulmonary function
JP6005657B2 (en) 2010-12-16 2016-10-12 ジェネンテック, インコーポレイテッド Diagnosis and treatment related to TH2 inhibition
TWI719112B (en) 2011-03-16 2021-02-21 賽諾菲公司 Uses of a dual v region antibody-like protein
BR112016008694A2 (en) 2013-10-23 2017-10-03 Genentech Inc METHODS FOR PREDICTING THE REACTION OF PATIENTS WITH ASTHMA, FOR PREDICTING THE ABILITY TO REACT IN PATIENTS WITH ASTHMA, FOR IDENTIFYING PATIENTS WITH ASTHMA, FOR TREATMENT OF PATIENTS WITH ASTHMA AND FOR TREATMENT OF ASTHMA, USE OF A KIT AND KIT
CN106029693A (en) 2014-02-21 2016-10-12 豪夫迈·罗氏有限公司 Anti-IL-13/IL-17 bispecific antibodies and uses thereof
WO2015155710A1 (en) 2014-04-11 2015-10-15 Novartis Ag Methods of selectively treating asthma using il-13 antagonists
CA2977285A1 (en) 2015-03-16 2016-09-22 F. Hoffmann-La Roche Ag Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
WO2017162604A1 (en) 2016-03-21 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and treatment of solar lentigo
EA037960B1 (en) 2016-04-27 2021-06-15 Эббви Инк. Method of treatment of eosinophilic esophagitis using an anti-il-13 antibody
JPWO2018135653A1 (en) * 2017-01-23 2020-01-09 学校法人 東洋大学 Anti-EPHA2 antibody and immunological detection of EPHA2 using the same
CN109776677B (en) * 2017-11-15 2023-11-03 尚华科创投资管理(江苏)有限公司 Humanized anti-IL-13 antibody and preparation method and application thereof
CN107909501B (en) * 2017-12-05 2020-12-01 创新先进技术有限公司 Correlation method of smell and behavior, smell socialization method and device
EP3749362A1 (en) 2018-02-09 2020-12-16 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
EP3938405A4 (en) * 2019-03-20 2022-12-28 Javelin Oncology, Inc. ANTI-ADAM12 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AND COMPOSITIONS AND METHODS COMPRISING THEM
GB201919062D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
CN119684453A (en) * 2024-12-19 2025-03-25 江苏荃信生物医药股份有限公司 Human IL-13 antibody, ELISA kit and detection method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060104943A1 (en) * 2002-08-30 2006-05-18 Claire Ashman Vaccine comprising il-13 and an adjuvant
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
DK2805728T3 (en) * 2003-12-23 2020-04-20 Genentech Inc New anti-IL13 antibodies and their applications
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins

Also Published As

Publication number Publication date
BRPI0706481A2 (en) 2011-03-29
IL192207A0 (en) 2008-12-29
EP1976881A2 (en) 2008-10-08
EA200801520A1 (en) 2009-02-27
TW200736274A (en) 2007-10-01
AR058955A1 (en) 2008-03-05
CN101370829A (en) 2009-02-18
JP2009523154A (en) 2009-06-18
PE20081185A1 (en) 2008-10-07
ZA200805526B (en) 2009-10-28
WO2007080174A2 (en) 2007-07-19
CA2635972A1 (en) 2007-07-19
NO20082767L (en) 2008-10-06
KR20080113201A (en) 2008-12-29
GB0600488D0 (en) 2006-02-22
AU2007204372A1 (en) 2007-07-19
MA30156B1 (en) 2009-01-02
WO2007080174A3 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
NO2025041I1 (en) Lecanemab
NL301163I2 (en) tafasitab
NO2021044I1 (en) isatuksimab
NO20190059A1 (en) Cyklopaminanaloger
CR10161A (en) IMMUNOGLOBULINS
AT504580A3 (en) SCAN-DEVICE
EP1996823A4 (en) NUT-RIVET
ATE546437T1 (en) AMINOMETHYL-4-IMIDAZOLE
DE602007004080D1 (en) TINTENSTRAHLAUFNEHMER
DE602007000333D1 (en) Napfbefestigungsvorrichtung
FI20061014A0 (en) Diffuusiopinnoitusmenetelmä
DE112007003147A5 (en) Pipe-bender
DE602007009334D1 (en) Garnerwärmungsvorrichtung
DE502007006319D1 (en) STAUBABSAUGADAPTERVORRICHTUNG
FI20060691A0 (en) Laitekotelointi
DE102006045567A8 (en) Crimpstabilisierung
NO20060756L (en) Transportsystem
ITMI20062042A1 (en) ELETTROVALVOLA
NO20065307L (en) Floteringsanordning
ITMI20061622A1 (en) CTRISTALLIZZATORE
FI20065768A0 (en) Eldstd
SE0700923L (en) Halogenhårtork
FR2896376B1 (en) DESHERBEUSE-EMIETTEUSE
FIU20060345U0 (en) Minigolf course
FI7405U1 (en) Bärplagg

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)